Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

Ages 30 to 39: One to five years of antidepressant use were around three times more likely to suffer sudden cardiac death.

Taking two common cholesterol drugs together could slash the risk of cardiovascular problems, a new study suggests ...

Some blood pressure medications are not the best choice anymore, either due to their side effects or limited effectiveness.

The Food and Drug Administration (FDA) has granted Fast Track designation to STM-01 for the treatment of heart failure with preserved ejection fraction ...

Some drugs are known as nephrotoxic, which means that their effects can cause damage to the kidneys. Drugs such as certain ...

A new study has found that combining statins - the first-line treatment for high cholesterol - and ezetimibe, another drug ...

Chanel Williams has met with government ministers to discuss the matter, saying: "I know that he would want this" The post ...

(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

Lorundrostat, an experimental drug, may help lower blood pressure in people with uncontrolled hypertension, researchers ...

The classification was in response to the mislabeling of coffee as decaf.